What is Basaglar KwikPen?
Basaglar KwikPen is an insulin glargine manufactured by Cipa Ltd. Basaglar KwikPen is made by recombinant DNA technology with a non-pathogenic laboratory strain of escherichia coli and differs from human insulin by the replacement of aspargine at the A21 position of A-chain with glycine and addition of two arginines to B31 and B32 of the B-chain.
Basaglar KwikPen contains 300 units or 3mL of a disposable single-patient use prefilled pen.
What Is It Used For?
Basaglar KwikPen is a long-acting insulin used to lower blood glucose levels in patients with type 1 and type 2 diabetes. It can be used with prandial insulin preparations and non-insulin anti-diabetic agents.
How Does It Work?
The duration of action of the Basaglar KwikPen is up to 24 hours and can be used for once-daily dosing. Insulin glargine is called “basal insulin” as it gives low concentrations of insulin and can keep blood sugar stable between meals. It is given with short-acting insulin or “bolus insulin” like insulin lispro, insulin glulisine, and insulin aspart to provide higher doses of insulin.
How to Take It?
Basaglar cartridges should be inserted in a Basaglar KwikPen. This medicine should be injected 15 minutes before meals or 20 minutes after meals. Pull a skin in the abdomen, thighs, or upper arms then administer the drug subcutaneously and make sure not to inject it in muscles or veins. Wait for 6 seconds before pulling the needle from the site of injection. Always rotate the administration site to avoid skin irritation.
The doctor will determine the correct dose for each patient who will be using the Basaglar KwikPen. The doctor will base this on the patient’s blood sugar tests and lifestyle. Do not take a double dose of insulin glargine.
Common side effects of the Basaglar KwikPen are low blood sugar, headache, dizziness, anxiety, nervousness, skin rashes, and pain or swelling at the injection site.
Warnings, Precautions and Contraindications
Blood sugar monitoring if the patient is having hypoglycaemic attacks or will develop allergic reactions to the ingredients of Basaglar KwikPen. It is unsafe to use this medication with alcohol and dose adjustment should be applied if the patient has renal or hepatic problems. The administration should not be used intramuscularly, intravenously, or in insulin pump administration. Sharing of Basaglar KwikPen or needles may cause serious infection. Always use a new and sterile needle for each injection.
Basaglar KwikPen may cause hypokalemia, hypoglycemia, amyloidosis at the site of injection, and the development of insulin antibodies. It can rarely affect visual impairment or will cause retinopathy and cataract. Lipohyperthrophy, lipoatrophy, and rare edema can occur at the site of administration of this drug. Severe or prolonged hypoglycemic episodes and allergic reactions can be potentially fatal to the patient.
Do not freeze or put the Basaglar KwikPen under direct sunlight. Only unopened pens should be stored in refrigerators ranging from 36-46°F (2-8°C) and at room temperature when in use within 28 days.
Put the used needles of Basaglar KwikPen in a heavy-duty and leak-resistant plastic container. Do not mix the used needles with household trash.